PRC
ABEO icon

Pearl River Capital’s Abeona Therapeutics ABEO Stock Holding History

Pearl River Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-48
Closed -$9K – 343
2018
Q4 		$9K Buy
+48
New +$10.5K 0.04% 585

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Pearl River Capital's ABEO Position: Q1 2019 in Review

Pearl River Capital sold out of Abeona Therapeutics (ABEO) in Q1 2019, closing a stake of 48 shares — an estimated $9K sold.

Pearl River Capital first reported a position in ABEO in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 87 funds tracked by Wall St. Rank hold ABEO as of Q1 2019.

  • Pearl River Capital reported no remaining Abeona Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 48 Abeona Therapeutics shares in Q1 2019, an estimated $9K.
  • Pearl River Capital first reported a position in Abeona Therapeutics in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Abeona Therapeutics position peaked at $9K in Q4 2018.
  • 87 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.